MTF Biologics and Kolosis BIO Introduce Novel Allografts to Advance Cardiac Surgery Outcomes
Key Insights
MTF Biologics (search) and Kolosis BIO (search) have partnered to launch ATLAS™ Sternal Repair Matrix and IKON™ Allograft Surgical Matrix, two innovative allografts designed for complex cardiac procedures.
ATLAS™, a demineralized cortical bone allograft, is inserted between sternal edges to enhance stabilization and fusion in challenging cases, offering an osteoconductive scaffold with proven bone-forming capacity.
IKON™ Allograft Surgical Matrix supports incision closure in high-risk patients by preserving growth factors and matrix proteins within a cell-friendly collagen structure.
MTF Biologics (search) and Kolosis BIO (search) have announced a strategic partnership to introduce two groundbreaking allograft tissues specifically designed for cardiac surgeons. The collaboration brings ATLAS™ Sternal Repair Matrix for sternal fusion and IKON™ Allograft Surgical Matrix for soft tissue repair to address critical needs in complex cardiac procedures, particularly for high-risk patients.
The announcement, made on May 22, 2025, represents a significant advancement in tissue engineering applications for cardiac surgery, where post-operative complications related to sternal healing remain a significant concern, especially in vulnerable patient populations.
"The MTF Biologics team is pleased to apply our proven allografts, developed in collaboration with surgeons across the nation, to transform sternal fusion and wound healing in the cardiac space," said Brad Bailey, Vice President and General Manager of MTF Biologics (search)' Orthopedic Franchise. "ATLAS and IKON will support clinicians caring for patients with complex challenges who are undergoing high-risk cardiac procedures."
ATLAS™ Sternal Repair Matrix: Enhancing Sternal Fusion
ATLAS Sternal Repair Matrix (search) represents a significant innovation in addressing sternal healing complications. This demineralized cortical bone allograft is designed to be inserted between sternal edges prior to closure, providing crucial support for stabilization and fusion in challenging patient cases.
The allograft has been specifically processed to preserve native growth factors and has undergone rigorous testing for osteoinductive potential. Key features of ATLAS include:
- Osteoconductive scaffold to support bone growth
- Rapid hydration capabilities for efficient surgical application
- Proven bone-forming capacity to enhance healing outcomes
These properties make ATLAS particularly valuable for patients with risk factors that may complicate sternal healing, such as diabetes, obesity, or advanced age.
IKON™ Allograft Surgical Matrix: Supporting Wound Closure
Complementing ATLAS, the IKON Allograft Surgical Matrix (search) addresses another critical aspect of cardiac surgery recovery. This innovative matrix is applied within subcutaneous tissue after sternal closure to support incision healing.
IKON's proprietary processing preserves essential growth factors and matrix proteins while maintaining a cell-friendly collagen structure. This combination of properties creates an optimal environment for wound closure in high-risk patients who may otherwise experience delayed healing or complications.
The introduction of IKON addresses a significant unmet need in cardiac surgery, where wound complications can lead to extended hospital stays, increased healthcare costs, and patient morbidity.
Expanding Horizons in Cardiac Surgery
For Kolosis BIO (search), this partnership represents a strategic expansion into new clinical territory. "For Kolosis, launching ATLAS and IKON in cardiac surgery is an exciting step into a new market, furthering our position as the premier pure-play biologics provider," said Collin Begley, CEO of Kolosis BIO. "These advanced allografts redefine standards for sternal repair and soft tissue repair, offering surgeons powerful new tools to improve outcomes."
The collaboration leverages MTF Biologics (search)' extensive expertise in tissue processing and allograft development with Kolosis BIO (search)'s market presence and distribution capabilities. MTF Biologics, a global nonprofit organization, has established itself as a leader in advancing tissue and organ donation, transplantation, and research.
Clinical Implications and Future Directions
The introduction of these specialized allografts comes at a time when cardiac surgery is increasingly performed on older patients with multiple comorbidities. Sternal complications, including dehiscence and wound infections, remain significant challenges in this population.
By providing surgeons with advanced biological tools specifically designed for these complex cases, MTF Biologics (search) and Kolosis BIO (search) aim to improve post-operative outcomes, potentially reducing complication rates and associated healthcare costs.
While specific clinical data on these new products was not detailed in the announcement, both companies emphasized that the allografts were developed in collaboration with surgeons nationwide, suggesting that their design incorporates practical clinical insights and addresses real-world surgical challenges.
As these products enter the cardiac surgery market, they will likely be subject to post-market surveillance to further evaluate their performance in diverse patient populations and surgical scenarios.
The partnership between MTF Biologics (search) and Kolosis BIO (search) represents a significant step forward in bringing tissue engineering innovations to cardiac surgery, potentially establishing new standards of care for sternal repair and soft tissue healing in this challenging clinical domain.